Actualités sur Medicale

01.11.2017 – 09:32
Takeda Pharmaceutical Company Limited
Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
Osaka, Japan (ots/PRNewswire) - New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for patients with ulcerative colitis or Crohn's disease Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced the ...
plus
31.10.2017 – 13:02
Novo Nordisk
New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care
Washington (ots/PRNewswire) - Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management ...
plus
30.10.2017 – 19:16
OrbusNeich
OrbusNeich's COMBO(TM) Dual Therapy Stent Demonstrates Non-inferiority vs the Market Leading XIENCE(TM) Everolimus Eluting Stent
Denver (ots/PRNewswire) - One-year results from the pivotal HARMONEE trial reported at TCT 2017 New results from the HARMONEE Japan/US Registration Trial, reported by OrbusNeich today in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, ...
plus
27.10.2017 – 21:18
InSightec
INSIGHTEC's Exablate Neuro Named Best Medical Technology at Esteemed Prix Galien Awards 2017
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (https://www.insightec.com/), the leader in MR-guided Focused Ultrasound (MRgFUS), has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation. Exablate Neuro is an innovative medical technology that uses focused ultrasound coupled with MR imaging (MRgFUS), to precisely target and treat areas deep ...
plus
26.10.2017 – 21:01
Merck Healthcare Germany
Merck Announces Recipients of EUR1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. based media. - Grant awarded across three research projects focused on prediction and defining characteristics of multiple sclerosis - Investment of EUR5 million in multiple sclerosis research funding as awards mark fifth year Merck, a leading science and ...
plus
26.10.2017 – 12:39
Merck Healthcare Germany
New Data at ECTRIMS Highlight Positive Benefit-Risk Profile of Mavenclad in Relapsing Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...
plus

25.10.2017 – 15:02
InSightec
INSIGHTEC Receives FDA Approval to Initiate Pivotal Study of Exablate Neuro for the Treatment of Patients with Parkinson's Disease
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (http://www.insightec.com), the world leader of MR-guided Focused Ultrasound announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia symptoms or motor ...
plus
25.10.2017 – 14:12
Merck Healthcare Germany
New Report Launched at ECTRIMS 2017 Highlights Unique Impact of MS on Women in Europe
Darmstadt, Germany (ots/PRNewswire) - - Multiple sclerosis diagnosis has a profound impact on life choices including education, career, family planning and relationships - Almost 90% of women say multiple sclerosis played a role in their separation or divorce following diagnosis - Policy interventions could help address significant gender-specific challenges Merck, a ...
plus
24.10.2017 – 10:00
Sequana Medical AG
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The ...
plus
23.10.2017 – 12:58
OrbusNeich
OrbusNeich Announces Schedule of Events at TCT 2017
Hong Kong (ots/PRNewswire) - - Program to include late-breaking presentation of REDUCE clinical trial - Data on more than 5,000 patients to be presented OrbusNeich, a global company specialising in the provision of life-changing vascular solutions, has today announced a schedule of events at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, ...
plus
19.10.2017 – 13:33
Accuray Europe
European Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy® System
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours (CHU). This most recent legal ruling marks ...
plus
19.10.2017 – 12:12
Teva Pharmaceutical Industries Ltd.
New Belief-based Patient Support Programme (PSP) Launched for People With Relapsing Multiple Sclerosis
Amsterdam (ots/PRNewswire) - Advanced MS Care Programme will offer tailored support for MS patients People living with relapsing forms of Multiple Sclerosis (MS) can now access a new Patient Support Programme (PSP) that offers tailored help based on their individual beliefs and support needs. Officially announced ...
plus

19.10.2017 – 10:00
Sequana Medical AG
Sequana Medical Announces 2017 AASLD Poster Presentation
Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that it will have a poster presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held October 20-24 in Washington, DC. Dr. Gijs Klarenbeek,MD, Chief Medical ...
plus
18.10.2017 – 12:36
Merck Healthcare Germany
Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...
plus
13.10.2017 – 08:57
OxThera AB
Dr. Bastian Dehmel Appointed CMO of OxThera
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary Hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal Phase III ...
plus
12.10.2017 – 09:00
Debiopharm International SA
GenePOC Launches its new GenePOC(TM) GBS DS test / GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe
Québec, Canada (ots) - GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce the launch of its 2nd assay this year, GenePOC(TM) GBS DS[1], for use on the revogene(TM) instrument. GenePOC GBS DS at intrapartum will aid to minimize the risk of GBS transmission from the mother to their ...
plus
04.10.2017 – 17:02
Intellijoint Surgical Inc.
Intellijoint Surgical Inc. Receives CE Mark Approval for Flagship Product intellijoint HIP®
Waterloo, Ontario (ots/PRNewswire) - Intellijoint Surgical®, a medical technology company, is pleased to announce that it has received the approval of the CE Mark (Conformité Européenne) for its intellijoint HIP® System in Europe. A 3D Mini-Optical Navigation System, intellijoint HIP® provides surgeons with ...
plus
04.10.2017 – 10:00
Sequana Medical AG
Sequana Medical Announces Publication of Results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T)
Zurich, Switzerland (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first ...
plus

03.10.2017 – 12:34
Merck Healthcare Germany
Merck Invests EUR 35 Million in its Italian Biotech Manufacturing Site of Bari
Bari, Italy (ots/PRNewswire) - - New production line for the aseptic filling of biotech medicines under isolator - Isolator technology represents best practice for the aseptic filling of injectable medicines and ensures the highest quality standards - Investment supports growth of Merck's portfolio of biotech medicines Merck, a leading science and technology company, ...
plus
03.10.2017 – 12:26
RWS Holdings
The acquisition of LUZ, Inc. and Corporate Translations, Inc. strengthens RWS' market leadership and continued growth of life science language services
Hartford, Connecticut (ots/PRNewswire) - On October 1, 2017 RWS, the world's leading provider of translation, intellectual property, life sciences and language support services, announced a re-launch of its brand, website and divisional structure following a number of successful acquisitions which have significantly ...
plus
29.09.2017 – 08:02
Novo Nordisk
IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes
Brussels (ots/PRNewswire) - - Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) - Globally, CVD is the most common cause of death in people with type 2 diabetes[1] - Results from this survey will help ...
plus
29.09.2017 – 08:00
Debiopharm International SA
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
plus
27.09.2017 – 10:04
Merck Healthcare Germany
Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
plus
26.09.2017 – 13:31
Accuray Europe
10-year Data Shows CyberKnife® System Provides Excellent Long-term Control of Low-Risk Prostate Cancer
Sunnyvale, California (ots/PRNewswire) - First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had ...
plus

26.09.2017 – 13:02
Medicago
Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine
Québec City (ots/PRNewswire) - The first plant-based seasonal flu vaccine candidate reaches final clinical stage Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, is proud to announce the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. ...
plus
21.09.2017 – 09:13
Merck Healthcare Germany
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
plus
20.09.2017 – 22:16
Accuray Europe
Accuray Showcases CyberKnife® and Radixact(TM) Systems at ASTRO 2017
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact(TM) Systems (http://www.accuray.com/product-overview) , and unique software solutions, will be shared by leading radiation oncology practitioners at the 2017 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California from ...
plus
20.09.2017 – 19:01
deCODE genetics
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome
Reykjavik, Iceland (ots/PRNewswire) - - The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases - Fathers pass on four times as many new mutations as mothers do, but the maternal contribution is particularly strong in 10% of the genome that is prone to double-strand breaks in the helix structure of DNA - These regions have been mutational hotspots for a very long time, and ...
plus
16.09.2017 – 13:57
Galderma
Galderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. The success of rosacea treatment is ...
plus
15.09.2017 – 09:32
Novo Nordisk
Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death
Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
plus

Précédent25262728293031323334Suivant